Human moricizine metabolism. II. Quantification and pharmacokinetics of plasma and urinary metabolites

Xenobiotica

Volumn 29, Issue 9, 1999, Pages 945-955

  Pieniaszek Jr , H J ^a   Davidson, A F ^a   Chaney, J E ^a,c   Shum, L ^a,d   Robinson, C A ^a   Mayersohn, M ^b  

^a DUPONT COMPANY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d Avantix Laboratories Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DRUG METABOLITE; MORACIZINE; PHENOTHIAZINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; VOLUNTEER;

ADULT; ANTI-ARRHYTHMIA AGENTS; CARBON RADIOISOTOPES; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MORICIZINE; REFERENCE VALUES;

EID: 0032830061     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982599238182     Document Type: Article

References (20)

1. BECKETT, A. H., BRAVEN, M. A. and ROBINSON, A. E., 1963, Metabolism of chlorpromazine in humans. Biochemical Pharmacology, 12, 779-794.
2. BENEDEK, L. H., DAVIDSON, A. F. and PIENTASZEK, H. J. JR, 1994, Enzyme induction by moricizine: time-course and extent in healthy subjects. Journal of Clinical Pharmacology, 34, 167-175.
3. BENEDEK, I. H., GARNER, D. M. and PIENIASZEK, H. J. JR, 1991, Dose proportionality of moricizine after escalating multiple doses in healthy volunteers. Journal of Clinical Pharmacology, 31, 229-232.
4. FITTON, A. and BUCKLEY, M. M.-T., 1990, Moricizine. A review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias. Drugs, 40, 138-167.
5. GIBALDI, M. and PERRIER, D., 1982, Pharmacokinetics, 2nd edn (New York: Marcel Dekker)
6. HOWRIE, D. L., PIENIASZEK, H. J. JR, FOGOROS, R. N., JUHL, R. P., SCHARY, W. L., WHITNEY, C. C. JR and DITTERT, L. W., 1987, Disposition of moracizine (Ethmozine) in healthy subjects. European Journal of Clinical Pharmacology, 32, 607-610.
7. LAM, F. C., HUNG, C. T. and PERRIER, D. G., 1985, Estimation of variance for harmonic mean half-lives. Journal of Pharmaceutical Sciences, 74, 229-231.
8. MANN, H. J., 1990, Moricizine: A new class I antiarrhythmic. Clinical Pharmacy, 9, 842-852.
9. MASSÉ, F. X. and MILLER, T., 1985, Exposure to radiation and informed consent. IRB, 7, 1-4.
10. MORGANROTH, J., PEARLMAN, A. S., DUNKMAN. W. B., HOROWITZ, L. N., JOSEPHSON, M. E. and MICHELSON, E. L., 1979, Ethmozin: a new antiarrhythmic agent developed in the USSR. Efficacy and tolerance. American Heart Journal, 98, 621-628.
11. MORGANROTH, J., 1990, Dose effect of moricizine on suppression of ventricular arrhythmias. American Journal of Cardiology, 65, 26D-31D.
12. PIÈNIASZEK, H. J. JR, CHANEY, J. E., SIGVARDSON, K. W., DAVIDSON, A. F., WHITNEY, C. C. JR, GAYLORD, J. C., ZEMAITIS, M. A., RAKESTRAW, D. C. and QUON, C. Y., 1990, Qualitative and quantitative aspects of moricizine metabolism. In Proceedings of the Third North American International Society for the Study of Xenobiotics Meeting, San Diego, CA, 21-25 October, 18 (abst).
13. PIENJASZEK, H. J. JR, DAVIDSON, A. F., McENTEGART, C. M., QUON, C. Y., SAMPLINER, R. E. and MAYERSOHN, M., 1994, The effect of hepatic disease on the disposition of moricizine in humans. Biopharmaceutics and Drug Disposition, 15, 243-252.
14. PIENIASZEK, H. J. JR, McENTEGART, C. M., MAYERSOHN, M. and MICHAEL, U. F., 1992, Moricizine pharmacokinetics in renal insufficiency: reevaluation of elimination half-life. The Journal of Clinical Pharmacology, 32, 412-414.
15. PIENIASZEK, H. J. JR, RAKESTRAW, D. C., SCHARY, W. L. and WILLIAMS, R. L., 1991, Influence of food on the oral absorption and bioavailability of moricizine. Journal of Clinical Pharmacology, 31, 792-795.
16. PIOTROVSKH, V. K., ROMINA, N. N., MERKULOVA, I. N., KURBANOV, R. D., METELITSA, V.I. and MAZAR, N. A., 1983, Bioavailability of ethmozine with oral administration. Khimiko-Farmatsevticheskii Zhurnal, 221, 912-916.
17. RICHARDS, L. E., PIENIASZEK, H. J. JR, SHATZMILLER, S., PAGE, G. O., BLOM, K. F., READ, J. M., DAVIDSON, A. F. and CONFALONE, P. N., 1997, Human moricizinc metabolism. I. Isolation and identification of metabolites in human urine. Xenobiotica, 27, 217-229.
18. SHELDON, R. S., HILL, R. J., TAOVIS, M. and WILSON, L. M., 1991, Aminoalkyl structural requirements for interaction of lidocaine with the class 1 antiarrhythmic receptor on rat cardiac myocytes. Molecular Pharmacology, 39, 609-614.
19. WECHSLER, M. E., STEINBERG, J. S. and GIARDINA, E.-G. V., 1991, Time course of moricizine'S effect on signal-averaged and 12-lead electrocardiograms: insights into mechanism of action. Journal of American College of Cardiology, 17, 1626-1633.
20. YANG, J. M. and CHAN, K., 1995, Isolation and characterization of sulphoxidation metabolites of moricizine in rat and human biological fluids. Methods and Findings in Experimental and Clinical Pharmacology, 17, 415-421.